Orion Oyj (HEL: ORNAV)

Market Cap	6.85B
Revenue (ttm)	1.43B
Net Income (ttm)	331.70M
Shares Out	n/a
EPS (ttm)	2.36
PE Ratio	20.66
Forward PE	n/a
Dividend	1.62 (3.29%)
Ex-Dividend Date	Oct 15, 2024

Volume	8,131
Average Volume	6,823
Open	48.90
Previous Close	48.60
Day's Range	48.90 - 49.95
52-Week Range	32.50 - 49.95
Beta	0.36
RSI	69.44
Earnings Date	Feb 25, 2025

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s diseas...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1917
• Employees: 3,632
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: ORNAV

Financial Performance

In 2023, Orion Oyj's revenue was 1.19 billion, a decrease of -11.26% compared to the previous year's 1.34 billion. Earnings were 216.80 million, a decrease of -37.97%.